The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.
 
Johan Hartman
Leadership - Stratipath AB
Stock and Other Ownership Interests - Stratipath AB
Honoraria - Lilly; MSD; Pfizer
Speakers' Bureau - Gilead Sciences
Research Funding - Cepheid (Inst); Cepheid (Inst); Novartis (Inst)
 
Robert Gray
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Genomic Health (Inst); GlaxoSmithKline (Inst); Janssen-Ortho (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Sequenta (Inst); Syndax (Inst); Takeda (Inst)
 
Mattias Rantalainen
Employment - Stratipath
Leadership - Stratipath AB
Stock and Other Ownership Interests - Stratipath AB
 
Stephanie Robertson
Employment - Stratipath AB
Stock and Other Ownership Interests - Stratipath AB
Honoraria - Novartis; Roche Diagnostics Solutions
 
Glenn Broeckx
No Relationships to Disclose
 
Christine Desmedt
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst)
Research Funding - Menarini Group (Inst)
Expert Testimony - Lilly (Inst)
 
Alexander Lazar
Leadership - Archer; Iterion Therapeutics; Modella; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; BMS; Deciphera; Moderna/Merck Collaboration; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Sunil Badve
Honoraria - Agilent Dako; Bristol Myers Squibb Foundation; Ventana Medical Systems
Consulting or Advisory Role - Agilent; Ventana Medical Systems
Speakers' Bureau - Agilent; AstraZeneca; Targos GmbH
Research Funding - Agilent Dako (Inst); Bristol Myers Squibb Foundation (Inst); Lilly (Inst)
Patents, Royalties, Other Intellectual Property - E-Score for predicting recurrence of DCIS (Inst); EarlyR - signature for ER+ breast cancer (Inst)
 
Sherene Loi
Honoraria - Adanate; Astra Zeneca / Daiichi Sankyo; Bicycle Therapeutics; BioNTech SE; Gilead Sciences; Menari Asia Pacific; Mersana; MSD Oncology; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Joseph Sparano
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; General Dynamics Information Technology (GDIT); Lyell Immunopharma; Novartis; NPJ Breast Cancer; Pfizer; UpToDate
Research Funding - Olema Pharmaceuticals (Inst)
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; AstraZeneca; BMS; Case45; Daicchii Sankyo; Roche
Speakers' Bureau - AstraZeneca; Daicchii Sankyo; Exact Sciences
Research Funding - Merck; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - AstraZeneca; Case45; Daichii Sankyo; Merck; Roche